Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. William Gradishar

Breast Oncology · NU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JPDr. Jong Chul Park

    Dr. Jong Chul Park

    Hematology & Oncology · Head & Neck Oncology
    Dana-Farber Cancer Institute
    jongchul

    Research

    Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

    2026

    Via Cancer Research Communications

    Research

    Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig

    2026

    Via Clinical Cancer Research

    Research

    Optimizing Induction Therapy for High-Risk Nasopharyngeal Carcinoma

    2026

    Via NEJM Evidence

    Research

    A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

    2025

    Via Clinical Cancer Research

    Research

    Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy

    2025

    Via JCO Precision Oncology

    Research

    Epigenetic Therapy Sensitizes Anti-PD-1 Refractory Head and Neck Cancers to Immunotherapy Rechallenge

    2025

    Via The Journal of Clinical Investigation

    Research

    Outcomes for Recurrent or Metastatic Head and Neck Cancer by HPV Status: A Systematic Review and Meta-Analysis

    2025

    Via The Oncologist

    Research

    Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Novel Therapeutic Development for Nasopharyngeal Carcinoma

    2025

    Via Current Oncology

    Research

    Interleukin-12 Anchored Drug Conjugate (Tolododekin Alfa) in Patients with Advanced Solid Tumors: First-in-Human Phase 1 Trial

    2025

    Via Nature Communications

    Research

    Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review

    2025

    Via JAMA Oncology

    Research

    Nivolumab with or without Ipilimumab in Patients with Recurrent or Metastatic Cervical Cancer (CheckMate 358): A Phase 1–2, Open-Label, Multicohort Trial

    2024

    Via The Lancet Oncology

    Research

    Final Outcomes Analysis of the Cell Product SQZ-PBMC-HPV Phase 1 Trial in Incurable HPV16+ Solid Tumors Shows Improved Overall Survival in Patients with Increased CD8+ T Cell Tumor Infiltration

    2024

    Via Molecular Carcinogenesis

    Research

    Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer

    2024

    Via JCO Precision Oncology

    Research

    Society for Immunotherapy of Cancer (SITC) Consensus Definitions for Resistance to Combinations of Immune Checkpoint Inhibitors with Chemotherapy

    2023

    Via Journal for Immunotherapy of Cancer